Access barriers and physician misperceptions are curbing uptake of Ardelyx's Xphozah in the dialysis hyperphosphatemia market, according to a new cross-study analysis from Spherix Global Insights. Nephrologists report they would nearly triple their use of Xphozah if reimbursement and coverage barriers were removed, yet current use stands at approximately one in ten dialysis patients. Physicians estimate that roughly one-third of treated hyperphosphatemia patients receive combination therapy, but Spherix patient chart data show the actual figure is closer to one in seven. The analysis also found that the proportion of patients who initiated and later discontinued Xphozah doubled over the past year to 8%, with gastrointestinal tolerability cited as the leading reason. These dynamics are set to intensify as the Transitional Drug Add-on Payment Adjustment expires at the end of 2026, moving phosphate-lowering therapies toward a bundled reimbursement model that no longer meaningfully differentiates products.
Ardelyx IncPhysician misperceptions and access barriers limit Xphozah uptake; discontinuation rate doubled; upcoming bundled reimbursement further reduces differentiation.